MicroRNAs as target molecular in metastatic liver cancer

MicroRNA作为转移性肝癌的靶分子

基本信息

批准号：
22590738
负责人：
MASAKI Tsutomu
金额：
$ 3万
依托单位：
Kagawa University
依托单位国家：
日本
项目类别：
Grant-in-Aid for Scientific Research (C)
财政年份：
2010
资助国家：
日本
起止时间：
2010 至 2012
项目状态：
已结题

来源：
https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-22590738/
关键词：
マイクロ RNA 転移性肝癌マイクロＲＮＡマイクロRNA

项目摘要

Objective: Recent studies suggest that metformin, which is a member of the biguanide family and commonly used as an oral anti-hyperglycemic agent, may reduce cancer risk and improve prognosis of numerous types of cancer. However, the mechanisms underlying metformin’s anti-tumor effect on gastric, esophageal, colon, pancreas, livercancers remain unknown. The goal of the present study was to evaluate the effects of metformin on the proliferation of various cancers in vitro, and to study changes in the expression profile of microRNAs (miRNAs), since miRNAs have previously been associated with the anti-tumor effects of metformin in other human cancers. Design: The human varios cacer cell lines, such as esophageal cancer cell lines T.T, KYSE30 and KYSE70, hepatocellular carcinoma cell lines HLE, HLF HiH7, Alex, colon cancer cell lines Caco 2, WiDr, Colo 320, pancreas cancer cell lines PK-1, PK-7 and Panc 1 were used to study the effects of metformin on human various cancers in vitro. In addition, we used miRNA array tips to explore the differences between miRNAs in some cancer cells with and without metformin treatment. Results: Metformin inhibited the proliferation of al cancer cells in vitro. Metformin blocked the cell cycle in G0/G1 in vitro. This blockade was accompanied by a strong decrease of G1 cyclins, especially cyclin D1, as well as decreases in cyclin-dependent kinase 4 (Cdk4), Cdk6, and phosphorylated retinoblastoma protein (Rb). In addition, the expression of miRNAs was markedly altered with the treatment of metformin in vitro.Conclusion: Metformin inhibited the growth of human cancer cell lines, and this inhibition may have involved reductions in cyclin D1, Cdk4 and Cdk6.

目的：最近的研究表明，二甲双胍是Biguanide家族的成员，通常用作口服抗血糖剂，可以降低癌症的风险并改善多种类型的癌症的预后。但是，二甲双胍对胃，食管，结肠，胰腺，肝癌的抗肿瘤作用的机制仍然未知。本研究的目的是评估二甲双胍对体外各种癌症增殖的影响，并研究microRNAS（miRNA）的表达谱的变化，因为miRNA以前与二甲双胍在其他人类癌症中的抗肿瘤作用有关。 Design: The human varios cacer cell lines, such as esophageal cancer cell lines T.T, KYSE30 and KYSE70, hepatocellular carcinoma cell lines HLE, HLF HiH7, Alex, colon cancer cell lines Caco 2, WiDr, Colo 320, pancreas cancer cell lines PK-1, PK-7 and Panc 1 were used to study the effects of metformin on human various cancers in vitro.此外，我们使用miRNA阵列尖端来探索一些有或不接受二甲双胍治疗的癌细胞中miRNA之间的差异。结果：二甲双胍在体外抑制了Al癌细胞的增殖。二甲双胍在体外阻断了G0/G1的细胞周期。这种封锁伴随着G1细胞周期蛋白，尤其是细胞周期蛋白D1的强烈降低，此外，通过在体外治疗二甲双胍的治疗：二甲双胍抑制人类癌细胞系的生长，这种抑制作用可能涉及环蛋白D1 D1 D1，CDK4和CDK4和CDK6。